JP2013532127A - イヌの炎症を診断、抑制および予防し、炎症状態を緩和するための方法 - Google Patents
イヌの炎症を診断、抑制および予防し、炎症状態を緩和するための方法 Download PDFInfo
- Publication number
- JP2013532127A JP2013532127A JP2013510177A JP2013510177A JP2013532127A JP 2013532127 A JP2013532127 A JP 2013532127A JP 2013510177 A JP2013510177 A JP 2013510177A JP 2013510177 A JP2013510177 A JP 2013510177A JP 2013532127 A JP2013532127 A JP 2013532127A
- Authority
- JP
- Japan
- Prior art keywords
- diet
- inflammation
- vitamin
- blood
- dogs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 23
- 230000004054 inflammatory process Effects 0.000 title claims abstract description 19
- 206010061218 Inflammation Diseases 0.000 title claims abstract description 18
- 230000004968 inflammatory condition Effects 0.000 title claims abstract description 8
- 241000282465 Canis Species 0.000 title description 3
- 230000002401 inhibitory effect Effects 0.000 title description 2
- 239000000090 biomarker Substances 0.000 claims abstract description 15
- 235000005911 diet Nutrition 0.000 claims abstract description 15
- 230000037213 diet Effects 0.000 claims abstract description 15
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 14
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 14
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims abstract description 8
- 230000036765 blood level Effects 0.000 claims abstract description 8
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 8
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 8
- 239000011718 vitamin C Substances 0.000 claims abstract description 8
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 8
- 239000011709 vitamin E Substances 0.000 claims abstract description 8
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 7
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 7
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 7
- 230000002829 reductive effect Effects 0.000 claims abstract description 7
- 229940046009 vitamin E Drugs 0.000 claims abstract description 7
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims abstract description 6
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims abstract description 6
- 201000008482 osteoarthritis Diseases 0.000 claims description 14
- 210000004369 blood Anatomy 0.000 claims description 12
- 239000008280 blood Substances 0.000 claims description 12
- 230000014509 gene expression Effects 0.000 claims description 12
- 235000021195 test diet Nutrition 0.000 claims description 7
- 108090000320 Hyaluronan Synthases Proteins 0.000 claims description 6
- 102000003918 Hyaluronan Synthases Human genes 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- CVYPRDPBCXSVBN-WDZFZDKYSA-N (5z)-5-[[5-[(4-chlorophenyl)methylsulfanyl]-1-methyl-3-(trifluoromethyl)pyrazol-4-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound C=1C=C(Cl)C=CC=1CSC=1N(C)N=C(C(F)(F)F)C=1\C=C1/SC(=S)NC1=O CVYPRDPBCXSVBN-WDZFZDKYSA-N 0.000 claims description 3
- 102100027400 A disintegrin and metalloproteinase with thrombospondin motifs 4 Human genes 0.000 claims description 3
- 102100032638 A disintegrin and metalloproteinase with thrombospondin motifs 5 Human genes 0.000 claims description 3
- 108091005664 ADAMTS4 Proteins 0.000 claims description 3
- 108091005663 ADAMTS5 Proteins 0.000 claims description 3
- 101000798762 Anguilla anguilla Troponin C, skeletal muscle Proteins 0.000 claims description 3
- 102100040006 Annexin A1 Human genes 0.000 claims description 3
- 102100027473 Cartilage oligomeric matrix protein Human genes 0.000 claims description 3
- 101710176668 Cartilage oligomeric matrix protein Proteins 0.000 claims description 3
- 102100020948 Growth hormone receptor Human genes 0.000 claims description 3
- 101000959738 Homo sapiens Annexin A1 Proteins 0.000 claims description 3
- 101001126865 Homo sapiens Biglycan Proteins 0.000 claims description 3
- 101001075287 Homo sapiens Growth hormone receptor Proteins 0.000 claims description 3
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 claims description 3
- 101001002634 Homo sapiens Interleukin-1 alpha Proteins 0.000 claims description 3
- 101000595904 Homo sapiens Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1 Proteins 0.000 claims description 3
- 101000990915 Homo sapiens Stromelysin-1 Proteins 0.000 claims description 3
- 101000620880 Homo sapiens Tartrate-resistant acid phosphatase type 5 Proteins 0.000 claims description 3
- 101000666340 Homo sapiens Tenascin Proteins 0.000 claims description 3
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 3
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims description 3
- 102100037850 Interferon gamma Human genes 0.000 claims description 3
- 102100020881 Interleukin-1 alpha Human genes 0.000 claims description 3
- 108090001005 Interleukin-6 Proteins 0.000 claims description 3
- 102000004889 Interleukin-6 Human genes 0.000 claims description 3
- 102100030608 Mothers against decapentaplegic homolog 7 Human genes 0.000 claims description 3
- 101100096242 Mus musculus Sox9 gene Proteins 0.000 claims description 3
- 102100035202 Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1 Human genes 0.000 claims description 3
- 102000014128 RANK Ligand Human genes 0.000 claims description 3
- 108010025832 RANK Ligand Proteins 0.000 claims description 3
- 101700026522 SMAD7 Proteins 0.000 claims description 3
- 102100030416 Stromelysin-1 Human genes 0.000 claims description 3
- 102100022919 Tartrate-resistant acid phosphatase type 5 Human genes 0.000 claims description 3
- 102100038126 Tenascin Human genes 0.000 claims description 3
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 claims description 3
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 claims description 3
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 claims description 3
- 229960002986 dinoprostone Drugs 0.000 claims description 3
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 claims description 3
- 102100030401 Biglycan Human genes 0.000 claims description 2
- 235000015097 nutrients Nutrition 0.000 claims description 2
- 230000009467 reduction Effects 0.000 claims description 2
- 230000002596 correlated effect Effects 0.000 claims 1
- 235000000891 standard diet Nutrition 0.000 claims 1
- 241000282472 Canis lupus familiaris Species 0.000 abstract description 33
- 206010003246 arthritis Diseases 0.000 abstract description 7
- 208000006820 Arthralgia Diseases 0.000 abstract description 3
- 230000003247 decreasing effect Effects 0.000 abstract description 2
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 description 15
- 210000001519 tissue Anatomy 0.000 description 7
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 6
- 230000003349 osteoarthritic effect Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 4
- 208000030175 lameness Diseases 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 3
- 210000000845 cartilage Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000000399 orthopedic effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 2
- -1 Xaa-propeptidase Proteins 0.000 description 2
- 230000002917 arthritic effect Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 235000020940 control diet Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 241000588807 Bordetella Species 0.000 description 1
- 208000000655 Distemper Diseases 0.000 description 1
- 206010065433 Ligament rupture Diseases 0.000 description 1
- 208000023178 Musculoskeletal disease Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 208000014058 canine distemper Diseases 0.000 description 1
- 230000008414 cartilage metabolism Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000002563 stool test Methods 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 238000005353 urine analysis Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/105—Osteoarthritis, e.g. cartilage alteration, hypertrophy of bone
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Feed For Specific Animals (AREA)
Abstract
【選択図】なし
Description
DHA+EPA:0.5〜2.5%
ビタミンC:75〜1000mg/kg
ビタミンE:250〜1000mg/kg
L−カルニチン:100〜1000mg/kg
を含む食餌、たとえばほぼ実施例1の被験食の栄養素組成をもつ食餌、たとえば乾燥重量基準でほぼ表1に示す量+/−10%の成分を含む食餌が含まれる。
[0009] 骨関節炎(OA)を伴うイヌに与えた場合に被験食が全血中の選択した関節炎関連遺伝子に及ぼす効果を評価するために試験を実施した。跛行および少なくとも1つの関節にOAに一致するX線像の変化を伴う31匹のビーグル犬(初期体重13.5±1.27kg、年齢11.0±2.23歳)を試験に含めた。すべてのイヌに対照である維持食を28日間与えた後、増加したレベルのEPAおよびDHA、ビタミンCおよびE、ならびにL−カルニチンを含有する被験食を与えた。対照食の最終日および被験食摂取14日後に全血試料を採集した。被験食を14日間摂取した後、これらのイヌに改善された整形学的検査スコアが認められた。被験配合物を14日間摂取した後、OAイヌは健康な高齢のイヌと比較してOAにおいてダウンレギュレートされることが先に立証された22の遺伝子(IL−6、ADAMTS−4、IFNG、HAS2、BGN、SOX−9、ADAMTS−5、MMP3、ACP5、IL1A、TNC、HAS3、COMP、IGF−1、GHR、Xaa−プロペプチダーゼ、RANKL、SMAD7、PGE2、TLR9、PLOD1、およびSCL2A9)の発現が増大し、アップレギュレートされることが先に示されたANXA1の発現が低下していた。まとめると、骨関節炎を伴うイヌに被験配合物を与えると、先に健康な高齢のイヌと比較して骨関節炎のイヌの血中にみられた遺伝子発現パターンが14日後に復帰していた。
Claims (9)
- イヌの炎症状態を検出する方法であって、1種類以上の炎症バイオマーカーの血中レベルを測定することを含み、その際、血中での発現の増大を組織における炎症の軽減と相関させる方法。
- 測定するバイオマーカーが、IL−6、ADAMTS−4、IFNG、HAS2、BGN、SOX−9、ADAMTS−5、MMP3、ACP5、IL1A、TNC、HAS3、COMP、IGF−1、GHR、Xaa−プロペプチダーゼ、RANKL、SMAD7、PGE2、TLR9、PLOD1、およびSCL2A9のうち1種類以上から選択される、請求項1に記載の方法。
- さらに、ANXA1の血中レベルを測定することを含み、その際、ANXA1レベルのレベル低下を組織における炎症の軽減と相関させる、請求項1または2に記載の方法。
- 標準食と比較して増加したレベルのDHA、EPA、ビタミンC、ビタミンE、および/またはL−カルニチンのうち1種類以上を含む食餌を与えることにより炎症状態を治療または抑制することを含む、請求項1、2または3に記載の方法。
- 前記の食餌を少なくとも2週間の期間与える、請求項4に記載の方法。
- 食餌が、乾燥重量基準で0.25〜5%の量のDHA+EPAを含む、請求項4または5に記載の方法。
- 食餌が、乾燥重量基準で
DHA+EPA:0.5〜2.5%
ビタミンC:75〜1000mg/kg
ビタミンE:250〜1000mg/kg
L−カルニチン:100〜1000mg/kg
を含む、請求項4に記載の方法。 - 食餌がほぼ実施例1の被験食の栄養素組成を有する、請求項4に記載の方法。
- 抑制または治療される状態が骨関節炎である、請求項1〜8のいずれか1項に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33408410P | 2010-05-12 | 2010-05-12 | |
US61/334,084 | 2010-05-12 | ||
PCT/US2011/035429 WO2011143048A2 (en) | 2010-05-12 | 2011-05-05 | Methods for the diagnosis, control and prophylaxis of inflammation and mitigation of inflammatory conditions in canines |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014246789A Division JP6078049B2 (ja) | 2010-05-12 | 2014-12-05 | イヌの炎症を診断、抑制および予防し、炎症状態を緩和するための方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2013532127A true JP2013532127A (ja) | 2013-08-15 |
JP6099560B2 JP6099560B2 (ja) | 2017-03-22 |
Family
ID=44260025
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013510177A Active JP6099560B2 (ja) | 2010-05-12 | 2011-05-05 | イヌの炎症を診断、抑制および予防し、炎症状態を緩和するための方法 |
JP2014246789A Active JP6078049B2 (ja) | 2010-05-12 | 2014-12-05 | イヌの炎症を診断、抑制および予防し、炎症状態を緩和するための方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014246789A Active JP6078049B2 (ja) | 2010-05-12 | 2014-12-05 | イヌの炎症を診断、抑制および予防し、炎症状態を緩和するための方法 |
Country Status (12)
Country | Link |
---|---|
US (2) | US10564169B2 (ja) |
EP (1) | EP2569639B1 (ja) |
JP (2) | JP6099560B2 (ja) |
CN (1) | CN102884434B (ja) |
AU (1) | AU2011253230B2 (ja) |
BR (1) | BR112012025841A2 (ja) |
CA (1) | CA2795575C (ja) |
DK (1) | DK2569639T3 (ja) |
ES (1) | ES2534246T3 (ja) |
RU (1) | RU2564089C2 (ja) |
WO (1) | WO2011143048A2 (ja) |
ZA (1) | ZA201208037B (ja) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104105967B (zh) * | 2011-12-12 | 2017-03-08 | 牛津大学科技创新有限公司 | 生腱蛋白c及其在类风湿关节炎的用途 |
CN103997904A (zh) * | 2011-12-13 | 2014-08-20 | 希尔氏宠物营养品公司 | 治疗牙病症的组合物和方法 |
CN107582576A (zh) * | 2017-10-11 | 2018-01-16 | 杭州鑫伟低碳技术研发有限公司 | 一种具有生物消炎功能的组合物及其制备方法 |
CA3119728A1 (en) | 2018-11-21 | 2020-05-28 | Tremeau Pharmaceuticals, Inc. | Purified forms of rofecoxib, methods of manufacture and use |
JP7241653B2 (ja) * | 2019-09-18 | 2023-03-17 | 株式会社ダイセル | 反射防止材 |
US11742069B2 (en) | 2021-02-01 | 2023-08-29 | Kpn Innovations, Llc. | Systems and methods for generating a nociception nourishment program |
US11161833B1 (en) | 2021-04-09 | 2021-11-02 | Tremeau Pharmaceuticals, Inc. | Deuterated etoricoxib, methods of manufacture, and use thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009536148A (ja) * | 2006-02-01 | 2009-10-08 | ネステク ソシエテ アノニム | 寿命を伸長するための栄養システム及び方法 |
WO2010009474A1 (en) * | 2008-07-18 | 2010-01-21 | Hill's Pet Nutrition, Inc. | Compositions and methods for treating osteoarthritis |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6156355A (en) * | 1998-11-02 | 2000-12-05 | Star-Kist Foods, Inc. | Breed-specific canine food formulations |
US8377904B2 (en) | 2004-02-09 | 2013-02-19 | Hill's Pet Nutrition, Inc. | Composition and method for use in cartilage affecting conditions |
WO2005110124A1 (en) | 2004-04-15 | 2005-11-24 | Abbott Laboratories | Composition and methods for nutritional management of patients with hepatic disease |
CN1997425B (zh) * | 2004-07-01 | 2010-10-13 | 雀巢技术公司 | 犬骨关节炎饮食配方 |
CA2586936C (en) | 2004-11-09 | 2019-08-20 | Hill's Pet Nutrition, Inc. | Use of antioxidants for gene modulation |
CN102907561A (zh) * | 2004-12-30 | 2013-02-06 | 希尔氏宠物营养品公司 | 提高老年动物的生活质量的方法 |
AU2005321817A1 (en) * | 2004-12-30 | 2006-07-06 | Hill's Pet Nutrition, Inc. | Methods for enhancing the quality of life of a growing animal |
US8252742B2 (en) * | 2004-12-30 | 2012-08-28 | Hill's Pet Nutrition, Inc. | Methods for enhancing the quality of life of a senior animal |
GB2426581A (en) * | 2005-05-27 | 2006-11-29 | Univ Nottingham | Immunoassay methods |
CN101247833B (zh) | 2005-06-29 | 2013-02-13 | 希尔氏宠物营养品公司 | 预防和治疗炎性疾病的方法和组合物 |
RU2008130860A (ru) | 2005-12-28 | 2010-02-10 | Хилл`С Пет Ньютришн, Инк. (Us) | Способ диагностики состояния массы тела или предрасположенности к нему у животных |
US7709215B2 (en) * | 2007-06-01 | 2010-05-04 | Cytonics Corporation | Method for diagnosing and treating acute joint injury |
AU2007356457B2 (en) * | 2007-07-09 | 2011-12-08 | Hill's Pet Nutrition, Inc. | Compositions and methods for reducing stool volume and stool odor |
US8906434B2 (en) | 2007-07-09 | 2014-12-09 | Hill's Pet Nutrition, Inc. | Compositions and methods for reducing stool volume and stool odor |
-
2011
- 2011-05-05 CA CA2795575A patent/CA2795575C/en active Active
- 2011-05-05 WO PCT/US2011/035429 patent/WO2011143048A2/en active Application Filing
- 2011-05-05 RU RU2012153681/15A patent/RU2564089C2/ru not_active IP Right Cessation
- 2011-05-05 ES ES11720361.2T patent/ES2534246T3/es active Active
- 2011-05-05 JP JP2013510177A patent/JP6099560B2/ja active Active
- 2011-05-05 US US13/642,576 patent/US10564169B2/en active Active
- 2011-05-05 DK DK11720361T patent/DK2569639T3/en active
- 2011-05-05 CN CN201180023613.1A patent/CN102884434B/zh not_active Expired - Fee Related
- 2011-05-05 EP EP11720361.2A patent/EP2569639B1/en active Active
- 2011-05-05 BR BR112012025841A patent/BR112012025841A2/pt not_active IP Right Cessation
- 2011-05-05 AU AU2011253230A patent/AU2011253230B2/en active Active
-
2012
- 2012-10-24 ZA ZA2012/08037A patent/ZA201208037B/en unknown
-
2014
- 2014-12-05 JP JP2014246789A patent/JP6078049B2/ja active Active
-
2020
- 2020-01-02 US US16/732,487 patent/US11143660B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009536148A (ja) * | 2006-02-01 | 2009-10-08 | ネステク ソシエテ アノニム | 寿命を伸長するための栄養システム及び方法 |
WO2010009474A1 (en) * | 2008-07-18 | 2010-01-21 | Hill's Pet Nutrition, Inc. | Compositions and methods for treating osteoarthritis |
Non-Patent Citations (3)
Title |
---|
"Effect of Prescription Diet canine j/d on whole blood gene expression in dogs with osteoarthritis", J VET INTERN MED, vol. 24, JPN6014011555, 7 May 2010 (2010-05-07), pages 771, ISSN: 0002771338 * |
HILL'S PRESCRIPTION DIET CANINE J/D, TROCHFUTTER, JPN6014011556, 1 December 2008 (2008-12-01), ISSN: 0002771339 * |
油脂・油糧ハンドブック, vol. 初版第一刷, JPN6014011552, 25 May 1988 (1988-05-25), pages 482 - 483, ISSN: 0002771337 * |
Also Published As
Publication number | Publication date |
---|---|
EP2569639B1 (en) | 2015-02-11 |
US20130041024A1 (en) | 2013-02-14 |
CN102884434B (zh) | 2015-08-19 |
BR112012025841A2 (pt) | 2016-06-28 |
US11143660B2 (en) | 2021-10-12 |
DK2569639T3 (en) | 2015-04-20 |
JP6078049B2 (ja) | 2017-02-08 |
AU2011253230B2 (en) | 2014-07-17 |
WO2011143048A2 (en) | 2011-11-17 |
JP6099560B2 (ja) | 2017-03-22 |
EP2569639A2 (en) | 2013-03-20 |
ES2534246T3 (es) | 2015-04-21 |
US10564169B2 (en) | 2020-02-18 |
US20200132699A1 (en) | 2020-04-30 |
CA2795575C (en) | 2017-02-28 |
RU2564089C2 (ru) | 2015-09-27 |
WO2011143048A3 (en) | 2012-01-05 |
CA2795575A1 (en) | 2011-11-17 |
ZA201208037B (en) | 2016-10-26 |
CN102884434A (zh) | 2013-01-16 |
JP2015096071A (ja) | 2015-05-21 |
RU2012153681A (ru) | 2014-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6078049B2 (ja) | イヌの炎症を診断、抑制および予防し、炎症状態を緩和するための方法 | |
Lau et al. | The role of I-FABP as a biomarker of intestinal barrier dysfunction driven by gut microbiota changes in obesity | |
AU2011253230A1 (en) | Methods for the diagnosis, control and prophylaxis of inflammation and mitigation of inflammatory conditions in canines | |
Raithel et al. | The measurement of leukotrienes in urine as diagnostic option in systemic mastocytosis | |
Summers et al. | Preliminary evaluation of fecal fatty acid concentrations in cats with chronic kidney disease and correlation with indoxyl sulfate and p‐cresol sulfate | |
Bruno et al. | Fecal Microbial Transplantation impact on gut microbiota composition and metabolome, microbial translocation and T-lymphocyte immune activation in recurrent Clostridium difficile infection patients | |
Wang et al. | Dietary zinc glycine supplementation improves tibia quality of meat ducks by modulating the intestinal barrier and bone resorption | |
Bailly et al. | Effects of dietary fat on the urinary risk factors of calcium stone disease | |
Noschka et al. | Implications of urine F2‐isoprostane metabolite concentration in horses with colic and its potential use as a predictor for surgical intervention | |
RU2530631C2 (ru) | Способ диагностики тяжести остеоартроза коленного сустава | |
Agreste et al. | Arthroscopic evaluation of the synovial membrane and its relationship with histological changes and biomarkers in equine joint disease | |
CN116949165B (zh) | 用于评估焦虑/抑郁-乳腺癌共患病的粪便标志物组及其应用 | |
Mikkola | It’s complex: studies on the genetics of canine hip dysplasia | |
JP2013528800A (ja) | ネコの炎症を診断、抑制および予防し、炎症状態を緩和するための方法 | |
Wang et al. | Intestinal microbes affect bile acid metabolism involved in gallstone formation | |
Wu et al. | Dietary fiber may benefit chondrocyte activity maintenance | |
Sanikop | Dual Energy Ct in the Evaluation of Gout and Its Corelation with Uric Acid Renal Calculi | |
CN115369156A (zh) | 一种自身免疫性疾病的肠型评分模型的构建方法及应用 | |
Alosami et al. | The Egyptian Rheumatologist | |
UA138715U (uk) | Спосіб прогнозування розвитку остеоартрозу | |
UA138718U (uk) | Спосіб прогнозування розвитку остеоартрозу | |
Hold et al. | PWE-012 Assessment of Bacterial Diversity in Colorectal Adenomatous Polyps | |
UA137798U (uk) | Спосіб прогнозування розвитку остеоартрозу | |
Eugênio et al. | Retrospective study of the feline lower urinary tract disease's cases between 2002 and 2009 admitted at Unesp-Araçatuba Veterinary Hospital. | |
JPWO2008096738A1 (ja) | 関節軟骨の変性又は損傷の検知方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140317 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140616 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140623 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140806 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20160413 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20160419 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160603 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161206 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170221 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6099560 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |